Chandra Bartholomeusz

2.9k total citations · 1 hit paper
44 papers, 2.0k citations indexed

About

Chandra Bartholomeusz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chandra Bartholomeusz has authored 44 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 26 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chandra Bartholomeusz's work include HER2/EGFR in Cancer Research (9 papers), Cancer-related Molecular Pathways (9 papers) and Melanoma and MAPK Pathways (7 papers). Chandra Bartholomeusz is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer-related Molecular Pathways (9 papers) and Melanoma and MAPK Pathways (7 papers). Chandra Bartholomeusz collaborates with scholars based in United States, Japan and United Kingdom. Chandra Bartholomeusz's co-authors include Naoto T. Ueno, Gabriel N. Hortobágyi, Dongwei Zhang, Ana M. González-Angulo, Hiroko Masuda, Hiroyoshi Doihara, Fumiyuki Yamasaki, Kevin N. Dalby, Francisco J. Esteva and Kaoru Kurisu and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

Chandra Bartholomeusz

42 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of epidermal growth factor receptor in breast cancer

2012 602 citations Hiroko Masuda, Dongwei Zhang et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chandra Bartholomeusz United States	24	1.2k	867	416	321	166	44	2.0k
Martin P. Barr Ireland	26	1.4k 1.2×	910 1.0×	728 1.8×	291 0.9×	166 1.0×	65	2.4k
Mei‐Chih Liang United States	20	1.3k 1.1×	702 0.8×	429 1.0×	360 1.1×	198 1.2×	30	2.2k
Lacey E. Dobrolecki United States	21	1.4k 1.2×	891 1.0×	412 1.0×	245 0.8×	204 1.2×	53	2.3k
Laurent Poulain France	29	1.6k 1.3×	645 0.7×	869 2.1×	212 0.7×	90 0.5×	79	2.6k
Loredana Cleris Italy	27	1.5k 1.2×	543 0.6×	325 0.8×	227 0.7×	107 0.6×	54	2.5k
Ana M. Tari United States	31	1.7k 1.5×	708 0.8×	367 0.9×	167 0.5×	161 1.0×	65	2.6k
Amro Aboukameel United States	31	2.0k 1.6×	1.0k 1.2×	611 1.5×	166 0.5×	123 0.7×	91	2.8k
Anette Sommer Germany	25	1.2k 1.0×	699 0.8×	323 0.8×	189 0.6×	59 0.4×	63	2.0k
Sheng-Chieh Hsu Taiwan	16	1.0k 0.9×	811 0.9×	364 0.9×	286 0.9×	51 0.3×	16	1.7k
Carolyn Cao United States	18	1.3k 1.0×	709 0.8×	402 1.0×	290 0.9×	53 0.3×	30	1.9k

Countries citing papers authored by Chandra Bartholomeusz

Since Specialization

Citations

This map shows the geographic impact of Chandra Bartholomeusz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chandra Bartholomeusz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chandra Bartholomeusz more than expected).

Fields of papers citing papers by Chandra Bartholomeusz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chandra Bartholomeusz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chandra Bartholomeusz. The network helps show where Chandra Bartholomeusz may publish in the future.

Co-authorship network of co-authors of Chandra Bartholomeusz

This figure shows the co-authorship network connecting the top 25 collaborators of Chandra Bartholomeusz. A scholar is included among the top collaborators of Chandra Bartholomeusz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chandra Bartholomeusz. Chandra Bartholomeusz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Villodre, Emilly S., et al.. (2026). Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis. Neuro-Oncology.

Hu, Xiaoding, Yun Xiong, Emilly S. Villodre, et al.. (2023). Abstract GS5-08: Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. Cancer Research. 83(5_Supplement). GS5–8. 1 indexed citations

Xie, Xuemei, Jangsoon Lee, Debu Tripathy, et al.. (2020). Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis. Molecular Cancer Therapeutics. 20(2). 296–306. 20 indexed citations

Gagliardi, Maria, Jihyun Park, Xuemei Xie, et al.. (2020). Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Scientific Reports. 10(1). 8537–8537. 28 indexed citations

Edupuganti, Ramakrishna, Qiantao Wang, Xuemei Xie, et al.. (2017). Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Bioorganic & Medicinal Chemistry. 25(9). 2609–2616. 29 indexed citations

Battula, Venkata Lokesh, Khoa Nguyen, Bin Yuan, et al.. (2017). IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. 8(23). 36936–36949. 28 indexed citations

Jose, Jiney, Clint D.J. Tavares, Nancy D. Ebelt, et al.. (2017). Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Medicinal Chemistry Letters. 8(10). 1072–1076. 23 indexed citations

Xie, Xuemei, Tamer S. Kaoud, Ramakrishna Edupuganti, et al.. (2016). c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 36(18). 2599–2608. 78 indexed citations

Bartholomeusz, Chandra, Xuemei Xie, Kimie Kondo, et al.. (2015). MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Molecular Cancer Therapeutics. 14(12). 2773–2781. 59 indexed citations

10.

Boulbés, Delphine R., et al.. (2015). CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Research and Treatment. 151(3). 501–513. 50 indexed citations

11.

Lee, Jangsoon, Chandra Bartholomeusz, Gabriel N. Hortobágyi, Peter Ordentlich, & Naoto T. Ueno. (2015). Abstract P6-14-01: A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression. Cancer Research. 75(9_Supplement). P6–14. 4 indexed citations

12.

Xie, Xinhua, Hailin Tang, Peng Liu, et al.. (2014). Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Letters. 356(2). 374–381. 9 indexed citations

13.

Kai, Kazuharu, Takayuki Iwamoto, Takashi Kobayashi, et al.. (2013). Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells. Oncogene. 33(4). 440–448. 8 indexed citations

14.

Masuda, Hiroko, Dongwei Zhang, Chandra Bartholomeusz, et al.. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment. 136(2). 331–345. 602 indexed citations breakdown →

15.

Hayashi, Naoki, Takayuki Iwamoto, Ana M. González-Angulo, et al.. (2011). Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. The Oncologist. 16(7). 956–965. 12 indexed citations

16.

Bartholomeusz, Chandra, Fumiyuki Yamasaki, Hitomi Saso, et al.. (2011). Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. Journal of Cancer. 2. 435–442. 23 indexed citations

17.

Itamochi, Hiroaki, Tomokazu Yoshida, Cheryl L. Walker, et al.. (2011). Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecologic Oncology. 122(3). 641–647. 20 indexed citations

18.

Bartholomeusz, Chandra, Daniel Rosen, Caimiao Wei, et al.. (2008). PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival. Cancer Research. 68(22). 9302–9310. 60 indexed citations

19.

Zhang, Dongwei, Ashutosh Pal, William G. Bornmann, et al.. (2008). Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics. 7(7). 1846–1850. 69 indexed citations

20.

Ueno, Naoto T., Chandra Bartholomeusz, John L. Herrmann, et al.. (2000). E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.. PubMed. 6(1). 250–9. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact